Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1145-1150

  De Vos, A I ^a   Nooter, K ^a   Verweij, J ^a   Loos, W J ^a   Brouwer, E ^a   De Bruijn, P ^a   Ruijgrok, E J ^b   Van Der Burg, M E L ^a   Stoter, G ^a   Sparreboom, A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cisplatin; Cremophor EL; Drug accumulation; Haematopoietic cells; Leukocytes; Paclitaxel

Indexed keywords

CISPLATIN; CREMOPHOR; PACLITAXEL; POLYSORBATE 80;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN MCF 7; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG FORMULATION; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; VERO CELL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; DRUG INTERACTIONS; GLYCEROL; HUMANS; LEUKOCYTES; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYSORBATES; SURFACE-ACTIVE AGENTS; VEHICLES;

EID: 9844220294     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008215720081     Document Type: Article

References (33)

1. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol™) and docetaxel (Taxotere™): Not simply two of a kind. Ann Oncol 1994; 5: 495-506.
2. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299-306.
3. Kano Y, Akutsu M, Tsunoda S et al. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 1996; 37: 525-30.
4. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993; 119: 727-33.
5. Milross CG, Peters LJ, Hunter NR et al. Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo. Int J Cancer 1995; 62: 599-604.
6. Rose WC. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 1993; 15: 47-53.
7. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
8. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-1703.
9. Pronk LC, Schellens JHM, Planting AST et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-9.
10. Schellens JHM, Ma J, Bruno R et al. Pharmacokinetics of cisplatin and Taxotere (docetaxel) and PBL DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/ Taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 1994; 13: 132 (Abstr).
11. Ma J, Verweij J, Planting AST et al. Current sample handling methods for measurement of cisplatin-DNA-adducts in leukocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair. Br J Cancer 1995; 71: 512-7.
12. Kessel D, Woodburn K, Decker D, Sykes E. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol Res 1995; 7: 207-12.
13. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
14. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 97: 77-89.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
16. Ma J, Verweij J, Planting AST et al. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 1996; 37: 382-4.
17. Sparreboom A, De Bruijn P, Nooter K et al. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography. J Chromatogr 1997; in press.
18. Loos WJ, Verweij J, Nooter K et al. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr 1997; 693: 437-41.
19. Sparreboom A, Loos WJ, Verweij J et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 1997; (submitted).
20. Planting AST, Kho GS, Van der Burg MEL et al. A Phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 347-52.
21. Van der Burg MEL, Logmans A, De Wit R et al. Six weeks of weekly high-dose cisplatin and daily oral Vepesid: A highly active regimen for ovarian cancer patients failing on or relapsing after conventional platinum containing combination chemotherapy. Proc Am Soc Clin Oncol 1996; 15: 285 (Abstr).
22. Sparreboom A, VanTellingen O, Huizing MT et al. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr 1996; 681: 355-61.
23. Van Tellingen O, Sparreboom A, Huizing MT et al. The analysis and preliminary pharmacokinetics of Cremophor EL in human plasma. Ann Oncol 1996; 7: 92 (Abstr).
24. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Non-linear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56: 2112-5.
25. Bertoncello I, Kriegler AB, Woodcock DM et al. Haematopoietic radioprotection by Cremophor EL: A polyethoxylated castor oil. Int J Radiat Biol 1995; 67: 57-64.
26. Woodcock DM, Linsenmeyer ME, Chojnowski G et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62-8.
27. Hoffmann H. Polyoxyäthylenglycerol tri-ricinoleat 35 DAC 1979. Pharm Zeit 1984; 30: 1730-3.
28. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 1993; 67: 1171-6.
29. Zhao F-K, Chuang LF, Israel M, Chuang RY. Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Res Commun 1989; 159: 1359-67.
30. Huizing MT, Giaccone G, Van Warmerdam LJC et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317-29.
31. Van Warmerdam LCJ, Huizing MT, Giaconne G et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997; 24 (Suppl 2): 97-104.
32. Kearns CM, Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24 (Suppl 2): 91-6.
33. Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 1997; 24 (Suppl 2): 85-90.